ESC 2017: The GLAGOV Trial - Stephen Nicholls

This interview with Stephen Nicholls from South Australian Health and Medical Research Institute, Adelaide, AU on the Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis (GLAGOV) at ESC 2017.

Filmed by Radcliffe Cardiology on-site at EASD 2017.

Video Category: 

  • Acute Coronary Syndromes
  • Atherosclerosis